← All trials
NCT05645276
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2023
- Primary completion
- Feb 28, 2025
- Completion date
- Feb 28, 2025
- First posted
- Dec 9, 2022
- Last posted
- Dec 9, 2022
- Enrollment
- 181
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Akeso Pharmaceuticals, Inc.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.